BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 25535987)

  • 1. What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram.
    Souery D; Calati R; Papageorgiou K; Juven-Wetzler A; Gailledreau J; Modavi D; Sentissi O; Pitchot W; Papadimitriou GN; Dikeos D; Montgomery S; Kasper S; Zohar J; Serretti A; Mendlewicz J
    World J Biol Psychiatry; 2015 Oct; 16(7):472-82. PubMed ID: 25535987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study.
    Balestri M; Calati R; Souery D; Kautzky A; Kasper S; Montgomery S; Zohar J; Mendlewicz J; Serretti A
    J Affect Disord; 2016 Jan; 189():224-32. PubMed ID: 26451508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
    Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A
    Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression--The EMC trial.
    Tadić A; Wachtlin D; Berger M; Braus DF; van Calker D; Dahmen N; Dreimüller N; Engel A; Gorbulev S; Helmreich I; Kaiser AK; Kronfeld K; Schlicht KF; Tüscher O; Wagner S; Hiemke C; Lieb K
    Eur Neuropsychopharmacol; 2016 Apr; 26(4):705-16. PubMed ID: 26899588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression.
    Olgiati P; Serretti A; Souery D; Dold M; Kasper S; Montgomery S; Zohar J; Mendlewicz J
    J Affect Disord; 2018 Feb; 227():777-786. PubMed ID: 29254066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clostridium butyricum MIYAIRI 588 as Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder: A Prospective Open-Label Trial.
    Miyaoka T; Kanayama M; Wake R; Hashioka S; Hayashida M; Nagahama M; Okazaki S; Yamashita S; Miura S; Miki H; Matsuda H; Koike M; Izuhara M; Araki T; Tsuchie K; Azis IA; Arauchi R; Abdullah RA; Oh-Nishi A; Horiguchi J
    Clin Neuropharmacol; 2018; 41(5):151-155. PubMed ID: 30234616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.
    Fabbri C; Crisafulli C; Calati R; Albani D; Forloni G; Calabrò M; Martines R; Kasper S; Zohar J; Juven-Wetzler A; Souery D; Montgomery S; Mendlewicz J; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2017 Dec; 267(8):723-735. PubMed ID: 28260126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial.
    Williams LM; Korgaonkar MS; Song YC; Paton R; Eagles S; Goldstein-Piekarski A; Grieve SM; Harris AW; Usherwood T; Etkin A
    Neuropsychopharmacology; 2015 Sep; 40(10):2398-408. PubMed ID: 25824424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of nonremission to antidepressant therapy using diffusion tensor imaging.
    Grieve SM; Korgaonkar MS; Gordon E; Williams LM; Rush AJ
    J Clin Psychiatry; 2016 Apr; 77(4):e436-43. PubMed ID: 27137427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of event-related potentials in predicting antidepressant treatment response: An iSPOT-D report.
    van Dinteren R; Arns M; Kenemans L; Jongsma ML; Kessels RP; Fitzgerald P; Fallahpour K; Debattista C; Gordon E; Williams LM
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):1981-90. PubMed ID: 26282359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontal and rostral anterior cingulate (rACC) theta EEG in depression: implications for treatment outcome?
    Arns M; Etkin A; Hegerl U; Williams LM; DeBattista C; Palmer DM; Fitzgerald PB; Harris A; deBeuss R; Gordon E
    Eur Neuropsychopharmacol; 2015 Aug; 25(8):1190-200. PubMed ID: 25936227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study.
    Rush AJ; South C; Jha MK; Jain SB; Trivedi MH
    J Clin Psychiatry; 2020 Aug; 81(5):. PubMed ID: 32780949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.
    McGrath PJ; Stewart JW; Fava M; Trivedi MH; Wisniewski SR; Nierenberg AA; Thase ME; Davis L; Biggs MM; Shores-Wilson K; Luther JF; Niederehe G; Warden D; Rush AJ
    Am J Psychiatry; 2006 Sep; 163(9):1531-41; quiz 1666. PubMed ID: 16946177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hippocampal Subfields in Acute and Remitted Depression-an Ultra-High Field Magnetic Resonance Imaging Study.
    Kraus C; Seiger R; Pfabigan DM; Sladky R; Tik M; Paul K; Woletz M; Gryglewski G; Vanicek T; Komorowski A; Kasper S; Lamm C; Windischberger C; Lanzenberger R
    Int J Neuropsychopharmacol; 2019 Aug; 22(8):513-522. PubMed ID: 31175352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The efficacy of esketamine in resistant major depressive disorder: A systematic review of the literature].
    Mungo A; Hein M
    Encephale; 2022 Aug; 48(4):455-461. PubMed ID: 35221019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
    Wu Z; Chen J; Yuan C; Hong W; Peng D; Zhang C; Cao L; Fang Y
    J Affect Disord; 2013 Sep; 150(3):834-9. PubMed ID: 23570952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, open-label prospective trial.
    Park HY; Lee BJ; Kim JH; Bae JN; Hahm BJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):318-23. PubMed ID: 22142651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial.
    Murrough JW; Wade E; Sayed S; Ahle G; Kiraly DD; Welch A; Collins KA; Soleimani L; Iosifescu DV; Charney DS
    J Affect Disord; 2017 Aug; 218():277-283. PubMed ID: 28478356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.